• Poly(I:C) as a Causal Probe of Cell Injury

  2026-08-24

  Poly (I:C), a synthetic double-stranded RNA analog, is more than an interferon inducer: it can function as a controlled perturbation for separating innate immune signaling from cell-death responses. This article connects TLR3 biology with practical assay design and the context-dependent framework of liver injury research.

• Berbamine hydrochloride for NF-κB Assays

  2026-08-23

  Berbamine hydrochloride supports mechanism-focused cancer research spanning NF-κB pathway interrogation, leukemia assays, and ferroptosis studies in HCC models. This workflow-led guide connects practical assay design with the METTL16-SENP3-LTF findings while distinguishing established product information from hypothesis-generating applications.

• AIBP–LRP2 Axis Restricts Collateral Vessel Growth

  2026-08-22

  Zhu et al. identify an AIBP–LRP2–HDL–miR-223 pathway that suppresses CXCR4-positive, stemlike capillary endothelial cells during collateral vessel formation. The work supports a two-phase model in which expanding capillary cells later acquire arterial characteristics, suggesting a mechanistic route for improving revascularization after ischemic injury.

• Novobiocin Sodium: From Gyrase to Translational Insight

  2026-08-22

  Novobiocin Sodium is more than a conventional antibacterial reference: it is a mechanistically anchored perturbation tool for linking DNA replication stress with host–pathogen phenotypes. This article examines the evidence, assay design principles, competitive context, and translational limits that should guide its use in advanced research workflows.

• From mRNA Tracking to Translational Confidence

  2026-08-21

  How fluorescent, modified reporter mRNA can connect delivery-system engineering with translational decision-making, using the ischemic stroke literature as a strategic case study.

• Hydroxytyrosol Assay Design for Cardiovascular Models

  2026-08-20

  Hydroxytyrosol assay design requires more than measuring antioxidant capacity. This guide translates cardiovascular model findings into practical decisions about compound identity, controls, concentration-response interpretation, and oxidative stress modulation.

• Rapamycin: mTOR Inhibition and PD-L1 Resistance

  2026-08-20

  Rapamycin and Sirolimus are best understood not only as potent mTOR inhibitors, but also as tools for dissecting adaptive immune-evasion biology. This article connects FKBP12–mTOR signaling with TFEB-driven PD-L1 expression and translates that mechanism into practical assay and workflow decisions.

• MHY1485: A Practical mTOR Activator Workflow

  2026-08-19

  MHY1485 provides a pharmacological way to activate mTOR while examining autophagy suppression, pathway-dependent proliferation, and tissue growth. This guide translates mTORC1 findings from nasopharyngeal carcinoma research into controlled signaling, autophagy, and ovarian follicle assay workflows, with practical troubleshooting for solubility and readout interpretation.

• MG-262 and Muscle Aging: A Proteostasis Strategy

  2026-08-19

  Muscle aging research is moving beyond single-pathway models of protein quality control. This thought-leadership article positions MG-262 (Z-Leu-Leu-Leu-B(OH)2) as a reversible pharmacological probe for separating proteasome function from chaperone-mediated autophagy, while providing a translational framework for proteasome inhibition assays, apoptosis research, and disease-relevant muscle models.

• HyperScribe Co-transcription mRNA Synthesis Kit Plus

  2026-08-18

  Build translation-ready, ARCA-capped and polyadenylated mRNA for vaccine research, reporter assays, RNAi, and mechanistic studies. This practical guide connects the HyperScribe workflow with an HCC nanovaccine study while separating validated product specifications from assay-specific optimization choices.

• ATRX Loss Sensitizes Glioma to RTK Inhibitors

  2026-08-18

  The reference study identifies ATRX deficiency as a potential genetic marker of increased sensitivity to multi-targeted receptor tyrosine kinase and PDGFR inhibitors in high-grade glioma cells. Its combination data with temozolomide support incorporating ATRX status into experimental design and the interpretation of RTK inhibitor trials, while remaining hypothesis-generating rather than clinically conclusive.

• Gastrodin, AT1 Signaling, and Reactive Astrocytes

  2026-08-17

  The 2024 study by Zuo and colleagues identifies a microglia-to-astrocyte signaling pathway in which inflammatory conditioned medium alters renin–angiotensin system components, SIRT3, and astrocyte phenotype markers. Its use of azilsartan to perturb AT1 signaling strengthens the case that AT1 participates in gastrodin-mediated regulation of reactive astrocytes, while also highlighting the complexity of interpreting A1/A2 marker changes.

• DiscoveryProbe FDA-approved Drug Library: Assay Guide

  2026-08-17

  Learn how DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) can support reproducible cell viability, proliferation, and cytotoxicity workflows through defined compound formatting, broad pharmacology, and practical screening design. The article connects assay optimization with drug repositioning screening and evidence-aware data interpretation.

• TAK-242: TLR4 Inhibition Workflow Guide

  2026-08-16

  TAK-242 (Resatorvid) provides a focused way to dissect LPS-triggered inflammation, macrophage phagocytosis, and host–pathogen signaling. This guide connects dose planning and assay controls with the recent Salmonella haem study, while separating validated evidence from practical workflow recommendations.

• Gramine: Reliable Ferroptosis Assay Workflows

  2026-08-15

  This scenario-based guide explains how Gramine (SKU N2337) can support reproducible viability, proliferation, and ferroptosis experiments in triple-negative breast cancer models. It connects published CUL3–MTDH findings with practical choices for stock preparation, controls, data interpretation, and product selection.

8192 records 1/547 page Next 12345 下5页 Last page